Sorafenib in advanced hepatocellular carcinoma

Llovet, Josep M., Ricci, Sergio, Mazzaferro, Vincenzo, Hilgard, Philip, Gane, Edward, Blanc, Jean-Frédéric, de Oliveira, Andre Cosme, Santoro, Armando +16 more·2008·New England Journal of Medicine
DOI 10.1056/nejmoa0708857

Cited by (1,037)

Items 401–500 of 1,037

  1. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy
    Yan Zhao, Yani Zhang, Kaiting Wang, Lei Chen · 2020 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  2. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics
    Roniel Cabrera · 2012 · Hepatic Medicine Evidence and Research
  3. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
    Youjin Je, Fabio A.B. Schutz, Toni K. Choueiri · 2009 · The Lancet Oncology
  4. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
    Julien Edeline, Éveline Boucher, Yan Rolland, Élodie Vauléon, Marc Pracht, Christophe Perrin, Catherine Le Roux, Jean‐Luc Raoul · 2011 · Cancer
  5. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
    Vishal Navnitray Ranpura, Sanjaykumar Hapani, Jeff Chuang, Shenhong Wu · 2010 · Acta Oncologica
  6. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
    Richard D. Kim, Debashis Sarker, Tim Meyer, Thomas C. C. Yau, Teresa Mercade Macarulla, Joong‐Won Park, Su Pin Choo, Antoine Hollebecque, Max W. Sung, Ho-Yeong Lim et al. · 2019 · Cancer Discovery
  7. KRAS: From undruggable to a druggable Cancer Target
    Uprety, Dipesh, Adjei, Alex A. · 2020 · Cancer Treatment Reviews
  8. The Ras/ MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications
    Bénédicte Delire, Peter Stärkel · 2015 · European Journal of Clinical Investigation
  9. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016
    Su Jong Yu · 2016 · Clinical and Molecular Hepatology
  10. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma
    Zhen Zhang, Xiangyang Zeng, Yinghua Wu, Yang Liu, Xi Zhang, Zewen Song · 2022 · Frontiers in Immunology
  11. Chemotherapy for hepatocellular carcinoma: current status and future perspectives
    Masafumi Ikeda, Chigusa Morizane, Makoto Ueno, Takuji Okusaka, Hiroshi Ishii, Junji Furuse · 2017 · Japanese Journal of Clinical Oncology
  12. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies
    Alqahtani, Ali, Khan, Zubair, Alloghbi, Abdurahman, S. Said Ahmed, Tamer, Ashraf, Mushtaq, M. Hammouda, Danae · 2019 · Medicina
  13. Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
    Sawada, Yu, Yoshikawa, Toshiaki, Nobuoka, Daisuke, Shirakawa, Hirofumi, Kuronuma, Toshimitsu, Motomura, Yutaka, Mizuno, Shoichi, Ishii, Hiroshi, Nakachi, Kohei, Konishi, Masaru et al. · 2012 · Clinical Cancer Research
  14. Therapeutic cancer vaccines: Are we there yet?
    Klebanoff, Christopher A., Acquavella, Nicolas, Yu, Zhiya, Restifo, Nicholas P. · 2011 · Immunological Reviews
  15. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
    Thierry de Baère, Yasuaki Arai, Riccardo Antonio Lencioni, Jean-François H. Geschwind, William S. Rilling, Riad Salem, Osamu Matsui, Michael C. Soulen · 2015 · CardioVascular and Interventional Radiology
  16. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
    Al B. Benson, Michael Ian D'Angelica, Daniel Erik Abbott, Thomas Adam Abrams, Steven R. Alberts, Daniel A. Anaya, Robert A. Anders, Chandrakanth Are, Daniel B. Brown, Daniel Tandel Chang et al. · 2019 · Journal of the National Comprehensive Cancer Network
  17. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality
    Marina Serper, Tamar Hamosh Taddei, Rajni L. Mehta, Kathryn D’Addeo, Feng Dai, Ayse Aytaman, Michelle L. Baytarian, Rena K. Fox, Kristel K. Hunt, David Seth Goldberg et al. · 2017 · Gastroenterology
  18. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
    Masahiro Matsuki, Taisuke Hoshi, Yuji Yamamoto, Megumi Ikemori Kawada, Yukinori Minoshima, Yasuhiro Funahashi, Junji Matsui · 2018 · Cancer Medicine
  19. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
    Thomas C. C. Yau, Chiun Hsu, Tae‐You Kim, Su-Pin Choo, Yoon‐Koo Kang, Ming‐Mo Hou, Kazushi Numata, Winnie Yeo, Akhil Chopra, Masafumi Ikeda et al. · 2019 · Journal of Hepatology
  20. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma
    Satoshi Shimizu, Tetsuo Takehara, Hayato Hikita, Takahiro Kodama, Hinako Tsunematsu, Takuya Miyagi, Atsushi Hosui, Hisashi Ishida, Tomohide Tatsumi, Tatsuya Kanto et al. · 2011 · International Journal of Cancer
  21. N1-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism
    Yanying Wang, Jing Wang, Xiaoyu Li, Xushen Xiong, Jianyi Wang, Ziheng Zhou, Xiaoxiao Zhu, Yang Gu, Dan Dominissini, Lei He et al. · 2021 · Nature Communications
  22. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension?
    Dominique Thabut, Vijay H. Shah · 2010 · Journal of Hepatology
  23. Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization
    Ahsun Riaz, Vanessa L. Gates, Bassel Atassi, Robert J. Lewandowski, Mary F. Mulcahy, Robert K. Ryu, Kent T. Sato, Talia Baker, Laura Kulik, Ramona Gupta et al. · 2010 · International Journal of Radiation Oncology*Biology*Physics
  24. Harnessing synthetic lethal interactions in anticancer drug discovery
    Denise A. Chan, Amato J. Giaccia · 2011 · Nature Reviews Drug Discovery
  25. Patterns of Response and Progression to Immunotherapy
    Édith Borcoman, Amara Gayathri Nandikolla, Georgina Venetia Long, Sanjay Goel, Christophe Le Tourneau · 2018 · American Society of Clinical Oncology Educational Book
  26. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
    Ann‐Lii Cheng, Zhongzhen Guan, Zhendong Chen, Chao-Jung Tsao, Shukui Qin, Jun Suk Kim, Tsai‐Sheng Yang, Won Young Tak, Hongming Pan, Shiying Yu et al. · 2012 · European Journal of Cancer
  27. Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma
    Mohamed Bouattour, Éric Raymond, Shukui Qin, Ann‐Lii Cheng, Uz M. Stammberger, Giuseppe Locatelli, Sandrine J. Faivre · 2017 · Hepatology
  28. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma
    Jian Chen, Julian A. Gingold, Xiaoping Su · 2019 · Trends in Molecular Medicine
  29. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
    A. Jindal, Anusha Thadi, K. Shailubhai · 2019 · Journal of Clinical and Experimental Hepatology
  30. Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
    María Reig, Jordi Rimola, Ferràn Torres, Anna Darnell, Carlos Rodríguez de Lope, Alejandro Forner, Neus Llarch, José Ríos, Carmen Ayuso, Jordi Bruix · 2013 · Hepatology
  31. The Inflammation and Liver Cancer
    Anupam Bishayee · 2014 · Advances in experimental medicine and biology
  32. Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria
    Daniel B. Brown, Jennifer E. Gould, Debra A. Gervais, Shraga Nahum Goldberg, Ravi Murthy, Steven F. Millward, William S. Rilling, Jean-François H. Geschwind, Riad Salem, Suresh Vedantham et al. · 2009 · Journal of Vascular and Interventional Radiology
  33. Mechanisms of Resistance to Anti-Angiogenic Therapy and Development of Third-Generation Anti-Angiogenic Drug Candidates
    Sonja Loges, Thomas Schmidt, Peter Carmeliet · 2010 · Genes & Cancer
  34. Sorafenib in Advanced Hepatocellular Carcinoma
    Denise M. Harnois · 2009 · Yearbook of Medicine
  35. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities
    Shuzhen Chen, Qiqi Cao, Wen Wen, Hongyang Wang · 2019 · Cancer Letters
  36. Practice guidelines for management of hepatocellular carcinoma 2009
    2009 · The Korean Journal of Hepatology
  37. Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC
    Pinyol, Roser, Sia, Daniela, Llovet, Josep M. · 2019 · Clinical Cancer Research
  38. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales
    Asmaa El-Kenawi, Azza B. El‐Remessy · 2013 · British Journal of Pharmacology
  39. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
    Jordi Bruix, Won Young Tak, Antonio Gasbarrini, Armando Santoro, M. Colombo, Ho-Yeong Lim, Vincenzo Mazzaferro, Reiner Wiest, María Reig, Andrea Wagner et al. · 2013 · European Journal of Cancer
  40. Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
    Augusto Villanueva, Beatriz Mínguez, Alejandro Forner, María Reig, Josep Maria Llovet · 2010 · Annual Review of Medicine
  41. Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
    Fumitaka Arihara, Eishiro Mizukoshi, Masaaki Kitahara, Yoshiko Takata, Kuniaki Arai, Tatsuya Yamashita, Yasunari Nakamoto, Shuichi Kaneko · 2013 · Cancer Immunology Immunotherapy
  42. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
    Shukui Qin, Qiu Li, Shanzhi Gu, Xiaoming Chen, Li-zhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren et al. · 2021 · The Lancet. Gastroenterology & hepatology
  43. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
    Jiang Chen, Renan Jin, Jie Zhao, Jinghua Liu, Hanning Ying, Han Yan, Senjun Zhou, Yuelong Liang, Diyu Huang, Xiao Huan Liang et al. · 2015 · Cancer Letters
  44. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis
    Husam Mohamed Abdel-Qadir, Josée-Lyne Ethier, Douglas S. Lee, Paaladinesh Thavendiranathan, Eitan Amir · 2016 · Cancer Treatment Reviews
  45. External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline
    Smith Apisarnthanarax, Aisling S Barry, Minsong Cao, Brian G. Czito, Ronald P. DeMatteo, Mary C. Drinane, Christopher Leigh Hallemeier, Eugene Jon Koay, Foster D. Lasley, Jeffrey John Meyer et al. · 2021 · Practical Radiation Oncology
  46. Prognosis of untreated hepatocellular carcinoma
    Edoardo Giovanni Giannini, Fabio Farinati, Francesca Ciccarese, Anna Pecorelli, Gian Lodovico Rapaccini, Mariella Di Marco, Luisa Benvegnù, Eugenio Caturelli, Marco Zoli, Franco Borzio et al. · 2014 · Hepatology
  47. Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
    Filip Jankú, David J. Stewart, Razelle Kurzrock · 2010 · Nature Reviews Clinical Oncology
  48. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence‐based comparison and review
    Zhi Ven Fong, Kenneth K. Tanabe · 2014 · Cancer
  49. Compassionate use of sorafenib in FLT3-ITD–positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
    Stephan Metzelder, Ying Wang, Ellen Wollmer, Michael Wanzel, Sabine Teichler, Anuhar Chaturvedi, Martin Eilers, Erich Enghofer, Andreas Neubauer, Andreas Burchert · 2009 · Blood
  50. Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program
    Guadalupe García–Tsao, Joseph K. Lim · 2009 · The American Journal of Gastroenterology
  51. Sorafenib in advanced hepatocellular carcinoma.
    G. Spinzi, S. Paggi · 2008 · New England Journal of Medicine
  52. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
    Robin Kate Kelley, Edward John Gane, Eric Assénat, Jürgen Siebler, Peter R. Galle, Philippe Merle, Isabelle Ollivier‐Hourmand, Ann Cleverly, Yumin Zhao, Ivelina Gueorguieva et al. · 2019 · Clinical and Translational Gastroenterology
  53. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment
    Chikezie O. Madu, Stephanie Y. Wang, Chinua O. Madu, Yi Wei Lu · 2020 · Journal of Cancer
  54. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)
    Haber, Philipp K., Puigvehí, Marc, Castet, Florian, Lourdusamy, Vennis, Montal, Robert, Tabrizian, Parissa, Buckstein, Michael, Kim, Edward, Villanueva, Augusto, Schwartz, Myron et al. · 2021 · Gastroenterology
  55. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling
    P Zhang, K-S Li, Y-h Shen, P-T Gao, Z-R Dong, J-B Cai, C Zhang, X-Y Huang, M-X Tian, Hu Zq et al. · 2016 · Cell Death and Disease
  56. Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis
    Xiaowei Zhang, Ping Zhang, Lin Kun An, Ningyuan Sun, Liying Peng, Weiwei Tang, Dingyuan Ma, Jun Chen · 2020 · Acta Pharmaceutica Sinica B
  57. Modern therapeutic approaches for the treatment of malignant liver tumours
    Henrik Petrowsky, Ralph Fritsch, Matthias Gückenberger, Michelle L. De Oliveira, Philipp Dutkowski, Pierre‐Alain Clavien · 2020 · Nature Reviews Gastroenterology & Hepatology
  58. Viral hepatocarcinogenesis
    W-L Tsai, Raymond T. Chung · 2010 · Oncogene
  59. Emerging immunotherapy for HCC: A guide for hepatologists
    Friedrich Foerster, Simon Johannes Gairing, Sumera Irie Ilyas, Peter R. Galle · 2022 · Hepatology
  60. Anti-VEGF therapies in the clinic
    Meadows, K. L., Hurwitz, H. I. · 2012 · Cold Spring Harbor Perspectives in Medicine
  61. Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
    Abdalla, Ahmed M.E., Xiao, Lin, Ullah, Muhammad Wajid, Yu, Miao, Ouyang, Chenxi, Yang, Guang · 2018 · Theranostics
  62. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake
    Kosuke Kaji, Norihisa Nishimura, Kenichiro Seki, Shinya Sato, Soichiro Saikawa, Keisuke Nakanishi, Masanori Furukawa, Hideto Kawaratani, Mitsuteru Kitade, Kei Moriya et al. · 2017 · International Journal of Cancer
  63. YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression
    Fitamant, Julien, Kottakis, Filippos, Benhamouche, Samira, Tian, Helen S., Chuvin, Nicolas, Parachoniak, Christine A., Nagle, Julia M., Perera, Rushika M., Lapouge, Marjorie, Deshpande, Vikram et al. · 2015 · Cell Reports
  64. Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
    Roy S. Herbst, David S. Hong, Linnea I. Chap, Razelle Kurzrock, Edward F. Jackson, Jeffrey M. Silverman, Erik Rasmussen, Yu‐Nien Sun, Zhong Don, Yuying C. Hwang et al. · 2009 · Journal of Clinical Oncology
  65. Tumor‐adjacent tissue co‐expression profile analysis reveals pro‐oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma
    Oleg V. Grinchuk, Surya Pavan Yenamandra, Ramakrishnan Iyer, Malay Singh, Hwee Kuan Lee, Kiat Hon Lim, Pierce K. H. Chow, Vladamir A. Kuznetsov · 2017 · Molecular Oncology
  66. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
    Ghassan K. Abou‐Alfa, Shukui Qin, Baek‐Yeol Ryoo, Sheng‐Nan Lu, C-J. Yen, Yin‐Hsun Feng, Ho Yeong Lim, Francesco Izzo, M. Colombo, Debashis Sarker et al. · 2018 · Annals of Oncology
  67. The role of telomeres and telomerase in cirrhosis and liver cancer
    Jean‐Charles Nault, Massih Ningarhari, Sandra Rebouissou, Jessica Zucman‐Rossi · 2019 · Nature Reviews Gastroenterology & Hepatology
  68. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
    Nishanth Murukesh, Caroline Dive, Gordon C. Jayson · 2009 · British Journal of Cancer
  69. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy
    Peter R. Galle, Francesco Tovoli, Friedrich Foerster, Marcus‐Alexander Wörns, Alessandro Cucchetti, Luigi Bolondi · 2017 · Journal of Hepatology
  70. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience
    Riad Salem, Ahmed Gabr, Ahsun Riaz, Ronald A. Mora, Rehan Ali, Michael M. Abecassis, Ryan Hickey, Laura Kulik, Daniel R. Ganger, Steven L. Flamm et al. · 2017 · Hepatology
  71. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma
    Lung‐Yi Mak, Vania Cruz-Ramón, Paulina Chinchilla-López, Harrys A. Torres, Noelle K. LoConte, John P. Rice, Lewis E. Foxhall, Erich M. Sturgis, Janette K. Merrill, Howard Harry Bailey et al. · 2018 · American Society of Clinical Oncology Educational Book
  72. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
    Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Vincent E. Gaillard, Anwaar Saeed, Brooke Wietharn et al. · 2022 · Hepatology
  73. Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma
    Desirée Bartolini, Katiuscia Dallaglio, Pierangelo Torquato, Marta Piroddi, Francesco Galli · 2017 · Translational research
  74. Cutaneous adverse effects of targeted therapies
    James B. Macdonald, Brooke Macdonald, Loren E. Golitz, Patricia Mucci LoRusso, Aleksandar Sekulić · 2015 · Journal of the American Academy of Dermatology
  75. Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations
    Xiao‐Dong Zhu, Cheng Huang, Ying‐Hao Shen, Yuan Ji, Ningling Ge, Xu-Dong Qu, Lingli Chen, Wen-Kai Shi, Meiling Li, Jinjin Zhu et al. · 2021 · Liver Cancer
  76. Targeting tumor angiogenesis with histone deacetylase inhibitors
    Leigh Ellis, Hans J. Hammers, Роберто Пили · 2008 · Cancer Letters
  77. Role of ferroptosis in hepatocellular carcinoma
    Jianhua Nie, Binlin Lin, Meng Zhou, Li Juan Wu, Tongsen Zheng · 2018 · Journal of Cancer Research and Clinical Oncology
  78. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
    L.-T. Chen, Erika Martinelli, Ann‐Lii Cheng, George E. Pentheroudakis, S. Qin, G.S. Bhattacharyya, Masafumi Ikeda, Ho Yeong Lim, Gwo Fuang Ho, Su Pin Choo et al. · 2020 · Annals of Oncology
  79. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
    Matthias Pinter, Bernhard Scheiner, Markus Peck‐Radosavljevic · 2020 · Gut
  80. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
    Josep M. Llovet, Robert Montal, Augusto Villanueva · 2019 · Journal of Hepatology
  81. Clinical development of targeted and immune based anti-cancer therapies
    Nicole A. Seebacher, Alexandra E. Stacy, Georgia Porter, Angelica M. Merlot · 2019 · Journal of Experimental & Clinical Cancer Research
  82. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management
    Hrishikesh V. Samant, Hosein Shokouh Amiri, Gazi B. Zibari · 2021 · Journal of Gastrointestinal Oncology
  83. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
    Masatoshi Kudo, Ana María Matilla, Armando Santoro, Ignacio Melero, Antonio Cubillo Gracián, Mirelis Acosta-Rivera, Su-Pin Choo, Anthony B. El-Khoueiry, Ryoko Kuromatsu, Bassel F. El‐Rayes et al. · 2021 · Journal of Hepatology
  84. Treatment Strategies for Hepatocellular Carcinoma—A Multidisciplinary Approach
    Isabella Lurje, Zoltán Czigány, Jan Bednarsch, Christoph Roderburg, Peter Isfort, Ulf P. Neumann, Georg Lurje · 2019 · International Journal of Molecular Sciences
  85. 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
    2019 · Korean Journal of Radiology
  86. Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
    Qingfeng Xiang, Weiqiang Chen, Meng Ren, Jingnan Wang, Hongwu Zhang, David Y.B. Deng, Lei Zhang, Changzhen Shang, Yajin Chen · 2014 · Clinical Cancer Research
  87. 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma
    Korean Liver Cancer Study Group · 2015 · Gut and Liver
  88. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance
    Xing Huang, Guangming Gan, Xiaoxiao Wang, Ting Xu, Wei Xie · 2019 · Autophagy
  89. REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
    Tatsuya Yamashita, Masatoshi Kudo, Kenji Ikeda, Namiki Izumi, Ryosuke Tateishi, Masafumi Ikeda, Hiroshi Aikata, Yasunori Kawaguchi, Yoshiyuki Wada, Kazushi Numata et al. · 2019 · Journal of Gastroenterology
  90. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma
    Lorenza Rimassa, Romano Danesi, Tiziana Pressiani, Philippe Merle · 2019 · Cancer Treatment Reviews
  91. Comparison of hepatocellular carcinoma in <scp>E</scp> astern versus <scp>W</scp> estern populations
    Choo, Su Pin, Tan, Wan Ling, Goh, Brian K. P., Tai, Wai Meng, Zhu, Andrew X. · 2016 · Cancer
  92. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
    María Reig, Ferràn Torres, Carlos Rodríguez de Lope, Alejandro Forner, Neus Llarch, Jordi Rimola, Anna Darnell, José Ríos, Carmen Ayuso, Jordi Bruix · 2014 · Journal of Hepatology
  93. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    S. Jelić, Georgios Charalambos Sotiropoulos · 2010 · Annals of Oncology
  94. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
    Ziyu Liu, Yan Lin, Jinyan Zhang, Yumei Zhang, Yongqiang Li, Zhihui Liu, Qian Li, Ming Luo, Rong Liang, Jiazhou Ye · 2019 · Journal of Experimental & Clinical Cancer Research
  95. Ironing out the role of ferroptosis in immunity
    Hannah Noelle Bell, Brent R. Stockwell, Weiping Zou · 2024 · Immunity
  96. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review
    Jean‐Marc Idée, Boris Guiu · 2013 · Critical Reviews in Oncology/Hematology
  97. Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
    Komlodi-Pasztor, Edina, Sackett, Dan L., Fojo, Antonio Tito · 2012 · Clinical Cancer Research
  98. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis
    Jiao Feng, Weiqi Dai, Yuqing Mao, Liwei Wu, Jingjing Li, Kan Chen, Qiang Yu, Rui Kong, Sainan Li, Jie Zhang et al. · 2020 · Journal of Experimental & Clinical Cancer Research
  99. Biomarkers for immunotherapy of hepatocellular carcinoma
    Greten, Tim F., Villanueva, Augusto, Korangy, Firouzeh, Ruf, Benjamin, Yarchoan, Mark, Ma, Lichun, Ruppin, Eytan, Wang, Xin W. · 2023 · Nature Reviews Clinical Oncology
  100. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
    María Reig, Marco Sanduzzi‐Zamparelli, Alejandro Forner, Jordi Rimola, Joana Ferrer, Marta Burrel, Ángeles García‐Criado, Alba Díaz, Neus Llarch, Gemma Iserte et al. · 2025 · Journal of Hepatology